{"id":"W3164041117","doi":"10.1136/annrheumdis-2021-eular.1862","title":"POS1050 SECUKINUMAB LEADS TO IMPROVEMENT ACROSS PSORIATIC ARTHRITIS MANIFESTATIONS OVER 2 YEARS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR: A POST HOC ANALYSIS OF FUTURE 5","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Krembil Foundation","funders":"Medac; Galápagos; Pfizer; Novartis Pharmaceuticals Corporation; Biogen; Celgene; Gilead Sciences; Regeneron Pharmaceuticals; Novartis; Amgen; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Secukinumab; Psoriatic arthritis; Dactylitis; Psoriasis; Psoriasis Area and Severity Index; Internal medicine; Enthesitis; Ustekinumab; Placebo; Clinical endpoint; Post-hoc analysis; Dermatology; Physical therapy; Surgery; Disease; Clinical trial; Adalimumab; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004726186,0.001550073,0.003245536,0.0004184594,0.0005808331,0.001421259,0.0008666134,0.001135008,0.007225953],"category_scores_gemma":[0.00389286,0.0004920522,0.004578958,0.0004019526,0.0007432562,0.001647768,0.0006808456,0.002674918,0.0006617851],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007211101,"about_ca_system_score_gemma":0.001008631,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001197448,"about_ca_topic_score_gemma":0.002174107,"domain_scores_codex":[0.9962607,0.001699267,0.0001975352,0.0007881231,0.0003104335,0.0007439151],"domain_scores_gemma":[0.9961103,0.002133245,0.0004820759,0.0004943307,0.0002468855,0.0005331635],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9405465,0.004893144,0.02438651,0.0002542223,0.006937928,0.0003611088,0.0001482335,0.0008833176,0.006049127,0.0001296599,0.001068809,0.01434151],"study_design_scores_gemma":[0.04520846,0.4910495,0.428562,0.00009167127,0.0141837,0.0004962375,0.000580404,0.008535421,0.007059539,0.0005926209,0.003460215,0.0001802322],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977254,0.0004619693,0.0002426523,0.0000942304,0.0001658462,0.00009034178,0.0004723686,0.00002110194,0.0007261555],"genre_scores_gemma":[0.9967051,0.0001735397,0.0002437148,0.0001190515,0.00009259035,0.0001687787,0.0005530529,0.00001042319,0.001933751],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007225953,"threshold_uncertainty_score":0.02499479,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0139316974614411,"score_gpt":0.313462660630752,"score_spread":0.2995309631693109,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}